Earlier in the year, Regeneron and partner Intellia Therapeutics, Inc. NTLA announced positive interim data from an ongoing phase I study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. Treatment with NTLA-2001 led to dose-dependent reductions in serum TTR and achieved maximal reductions by day 28. Intellia expects to complete enrollment of the phase I study for both ATTRv-PN and ATTR-CM subjects in 2022 and present additional data at a medical meeting later this year. Intellia and Regeneron plan to move toward pivotal studies for both forms of ATTR amyloidosis, with an initial focus on the cardiomyopathy manifestations of the disease. Regeneron has a solid and diverse portfolio, which is expected to maintain the company's momentum further despite stiff competition for its key drugs.